Karen Akinsanya Schrodinger, Inc. (SDGR) insider trading activity

Karen Akinsanya is President of R&D, Therapeutics of Schrodinger, Inc.. Currently has a direct ownership of 15,625 shares of SDGR, which is worth approximately $329,375. The most recent transaction as insider was on Mar 03, 2025, when has been sold 15,625 shares (Common Stock) at a price of $0.0 per share, resulting in proceeds of $0. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 15.6K

Infinity% 3M change

Infinity% 12M change

Total Value Held $329,375

Karen Akinsanya Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 03 2025	BUY Grant, award, or other acquisition	-	15,625 Added 50.0%	15,625 Common Stock
Oct 15 2021	SELL Open market or private sale	$77,660 $55.75 p/Share	1,393 Reduced 100.0%	0 Common Stock
Oct 15 2021	BUY Exercise of conversion of derivative security	$6,046 $4.34 p/Share	1,393 Added 50.0%	1,393 Common Stock
Sep 15 2021	SELL Open market or private sale	$85,215 $61.13 p/Share	1,394 Reduced 100.0%	0 Common Stock
Sep 15 2021	BUY Exercise of conversion of derivative security	$6,050 $4.34 p/Share	1,394 Added 50.0%	1,394 Common Stock
Aug 16 2021	SELL Open market or private sale	$2,181,256 $57.8 p/Share	37,738 Reduced 100.0%	0 Common Stock
Aug 16 2021	BUY Exercise of conversion of derivative security	$309,074 $8.19 p/Share	37,738 Added 50.0%	37,738 Common Stock
Jun 08 2021	SELL Open market or private sale	$776,241 $75.79 p/Share	10,242 Reduced 100.0%	0 Common Stock
Jun 08 2021	BUY Exercise of conversion of derivative security	$44,450 $4.34 p/Share	10,242 Added 50.0%	10,242 Common Stock
Jun 07 2021	SELL Open market or private sale	$486,573 $75.1 p/Share	6,479 Reduced 100.0%	0 Common Stock
Jun 07 2021	BUY Exercise of conversion of derivative security	$28,119 $4.34 p/Share	6,479 Added 50.0%	6,479 Common Stock
Dec 18 2020	SELL Open market or private sale	$1,070,160 $80.0 p/Share	13,377 Reduced 100.0%	0 Common Stock
Dec 18 2020	BUY Exercise of conversion of derivative security	$43,074 $3.22 p/Share	13,377 Added 50.0%	13,377 Common Stock

Also insider at

NAUT

Nautilus Biotechnology, Inc. Healthcare

Director

Karen Akinsanya

President of R&D, Therapeutics

New York, NY

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells SDGR shares.

Notify only if

Value

Insider Trading

Get notified when an Schrodinger, Inc. insider buys or sells SDGR shares.

Notify only if

Operation

Value

Type

News

Receive news related to Schrodinger, Inc.

Track Activities on SDGR

Account